Med Biogene Records Loss of US$117K in Q1 | GenomeWeb

NEW YORK (GenomeWeb News) – Med Biogene today said that it had a loss of C$120,701 (US$117,357) for the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm had EPS of breakeven, compared to a loss of C$196,551, or breakeven EPS, a year ago.

Med Biogene did not disclose its revenues for the quarter and its quarterly earnings document was not yet available online from Canadian regulators.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.